Want to see DE:B8FK full AI Analyst Report?
Top Page
Biofrontera
(XETRA:B8FK)
Select Model
Select Model
Rating:51Neutral
Price Target:
€3.50
▲(38.34% Upside)
Action:Reiterated
Date:10/06/26
The score is held back primarily by weak financial performance—ongoing net losses and multi-year negative operating/free cash flow—despite low debt levels and strong gross margins. Technicals are a meaningful positive, with price above major moving averages and positive momentum indicators. Valuation remains a secondary drag due to the negative P/E and lack of dividend yield data.
Positive Factors
Strong Gross Margin
An approximately 83% gross margin indicates that Biofrontera’s dermatology products retain substantial value after direct costs. If sales recover, this margin structure could support operating leverage and provide room to fund commercial activities, development, and market expansion.
Negative Factors
Persistent Net Losses
Persistent net losses show that Biofrontera has not yet converted its strong gross margin into sustainable company-wide profitability. Continued operating deficits can restrict investment capacity, increase reliance on external funding, and make earnings improvement dependent on a meaningful recovery in revenue or costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margin
An approximately 83% gross margin indicates that Biofrontera’s dermatology products retain substantial value after direct costs. If sales recover, this margin structure could support operating leverage and provide room to fund commercial activities, development, and market expansion.
Read all positive factors
Biofrontera (B8FK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€22.36M
Dividend YieldN/A
Average Volume (3M)2.30K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue GrowthN/A
EPS GrowthN/A
CountryDE
Employees73
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,076,862
10 Day Avg. Volume5,593
30 Day Avg. Volume2,302
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)0.99
Price to Sales (P/S)1.12
P/FCF Ratio-3.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biofrontera Business Overview & Revenue Model
Company Description
Biofrontera AG operates as a biopharmaceutical company specializing in dermatology. It conducts research, development, and commercialization of skin-related products across Germany, Spain, the United Kingdom, the broader European continent, the Un...
How the Company Makes Money
Biofrontera makes money primarily by selling prescription dermatology products and associated photodynamic therapy (PDT) equipment into clinical channels. The core revenue stream historically has been product sales of Ameluz (topical gel used as a...
Biofrontera Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
67
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.25M | 13.19M | 12.18M | 32.25M | 25.74M | 28.79M |
| Gross Profit | 26.00M | 10.91M | 10.12M | 25.37M | 20.98M | 24.87M |
| EBITDA | -172.00K | -560.00K | -301.00K | 5.57M | 2.34M | -12.59M |
| Net Income | -369.00K | -3.96M | -4.35M | -369.00K | -44.17M | 37.75M |
Balance Sheet | ||||||
| Total Assets | 30.73M | 20.64M | 30.15M | 30.73M | 32.73M | 76.13M |
| Cash, Cash Equivalents and Short-Term Investments | 3.08M | 3.62M | 3.28M | 3.08M | 6.38M | 6.91M |
| Total Debt | 1.15M | 626.00K | 765.00K | 1.15M | 1.50M | 3.30M |
| Total Liabilities | 10.75M | 5.80M | 11.30M | 10.75M | 12.39M | 18.70M |
| Stockholders Equity | 19.98M | 14.90M | 18.86M | 19.98M | 20.34M | 57.43M |
Cash Flow | ||||||
| Free Cash Flow | 772.00K | -4.45M | -2.75M | -2.83M | -4.88M | 29.81M |
| Operating Cash Flow | 772.00K | -4.40M | -2.54M | -1.92M | -3.90M | 30.44M |
| Investing Cash Flow | 0.00 | 5.33M | -210.00K | -912.00K | -981.00K | -42.26M |
| Financing Cash Flow | 0.00 | -452.00K | 2.79M | -467.00K | 4.34M | 2.18M |
Biofrontera Technical Analysis
Positive
2.53
Price Trends
2.68
Positive
2.55
Positive
2.54
Positive
Market Momentum
0.31
Negative
67.05
Neutral
39.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:B8FK, the sentiment is Positive. The current price of 2.53 is below the 20-day moving average (MA) of 2.95, below the 50-day MA of 2.68, and below the 200-day MA of 2.54, indicating a bullish trend. The MACD of 0.31 indicates Negative momentum. The RSI at 67.05 is Neutral, neither overbought nor oversold. The STOCH value of 39.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:B8FK.
Biofrontera Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €772.79M | 15.00 | 19.49% | 1.83% | 4.42% | 35.68% | |
65 Neutral | €1.86B | 13.52 | 22.38% | 2.35% | 0.39% | 38.58% | |
63 Neutral | €59.52B | 24.96 | 8.08% | 1.62% | -0.40% | -17.22% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €22.36M | -1.48 | -127.78% | ― | ― | ― | |
43 Neutral | €109.94M | -3.36 | 444.89% | ― | 77.97% | -41.49% | |
41 Neutral | €518.77M | -2.67 | -26.46% | ― | -7.72% | -26.61% |
* General Sector Average
DE:B8FK
Biofrontera
3.38
0.54
19.01%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
12.00
-5.52
-31.50%
DE:EVT
Evotec
2.96
-3.94
-57.06%
DE:MRK
Merck KGaA
136.05
18.21
15.46%
DE:HPHA
Heidelberg Pharma AG
2.35
-0.83
-26.10%
DE:DMP
Dermapharm Holding SE
37.45
4.77
14.58%
Biofrontera Corporate Events
Financial DisclosuresRegulatory Filings and Compliance
Biofrontera Sets Date for Release of 2026 Half-Year Results
Neutral
Sep 30, 2026
Biofrontera AG has announced the scheduled publication of its half-year financial report for 2026, covering the period from 1 January to 30 June 2026. The report is set to be released on 30 September 2026 and will be made available to investors vi...
Business Operations and StrategyDelistings and Listing Changes
Biofrontera Plans Move from Prime Standard to Frankfurt’s Scale Segment
Neutral
Jul 28, 2026
Biofrontera AG’s management board, with supervisory board approval, has decided to prepare a transfer of its stock exchange listing from the regulated market’s Prime Standard to the Scale segment of the Frankfurt Stock Exchange’s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.